PATRYS Ltd Cash Flow Conversion Efficiency
PATRYS Ltd cash flow conversion efficiency. Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PATRYS Ltd (2008–2025)
Cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for PATRYS Ltd for real-time trading data and today's change.
PATRYS Ltd Cash Flow Conversion Ratio Explained
PATRYS Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PATRYS Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency. Also see market cap of PATRYS Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASN Broker Public Company Limited
BK:ASN
|
0.027x |
|
Fobi AI Inc
V:FOBI
|
0.070x |
|
XiDeLang Holdings Ltd
KLSE:5156
|
-0.142x |
|
Evion Group NL
AU:EVG
|
-0.122x |
|
Myseum, Inc.
NASDAQ:MYSE
|
-0.159x |
|
Llama Group S.A.
PA:ALLAM
|
0.411x |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
-0.438x |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
0.042x |
Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. Review PAB free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$732.87K ≈ $518.56K |
AU$-1.77 Million ≈ $-1.26 Million |
-2.421x | -362.62% |
| 2024-06-30 | AU$3.47 Million ≈ $2.46 Million |
AU$-1.82 Million ≈ $-1.28 Million |
-0.523x | +38.08% |
| 2023-06-30 | AU$6.84 Million ≈ $4.84 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-0.845x | -30.75% |
| 2022-06-30 | AU$13.43 Million ≈ $9.50 Million |
AU$-8.68 Million ≈ $-6.14 Million |
-0.646x | -100.76% |
| 2021-06-30 | AU$12.04 Million ≈ $8.52 Million |
AU$-3.88 Million ≈ $-2.74 Million |
-0.322x | +37.06% |
| 2020-06-30 | AU$4.88 Million ≈ $3.45 Million |
AU$-2.50 Million ≈ $-1.77 Million |
-0.512x | -2789.46% |
| 2019-06-30 | AU$7.30 Million ≈ $5.16 Million |
AU$-129.19K ≈ $-91.41K |
-0.018x | +93.81% |
| 2018-06-30 | AU$7.29 Million ≈ $5.16 Million |
AU$-2.09 Million ≈ $-1.48 Million |
-0.286x | +40.32% |
| 2017-06-30 | AU$2.66 Million ≈ $1.88 Million |
AU$-1.28 Million ≈ $-903.55K |
-0.480x | -13.93% |
| 2016-06-30 | AU$3.64 Million ≈ $2.57 Million |
AU$-1.53 Million ≈ $-1.08 Million |
-0.421x | +59.39% |
| 2015-06-30 | AU$3.97 Million ≈ $2.81 Million |
AU$-4.11 Million ≈ $-2.91 Million |
-1.036x | -153.21% |
| 2014-06-30 | AU$12.43 Million ≈ $8.80 Million |
AU$-5.09 Million ≈ $-3.60 Million |
-0.409x | -67.78% |
| 2013-06-30 | AU$10.77 Million ≈ $7.62 Million |
AU$-2.63 Million ≈ $-1.86 Million |
-0.244x | +19.13% |
| 2012-06-30 | AU$12.45 Million ≈ $8.81 Million |
AU$-3.75 Million ≈ $-2.66 Million |
-0.302x | +20.56% |
| 2011-06-30 | AU$13.47 Million ≈ $9.53 Million |
AU$-5.11 Million ≈ $-3.62 Million |
-0.380x | +18.00% |
| 2010-06-30 | AU$15.23 Million ≈ $10.78 Million |
AU$-7.05 Million ≈ $-4.99 Million |
-0.463x | -13.05% |
| 2009-06-30 | AU$17.72 Million ≈ $12.54 Million |
AU$-7.26 Million ≈ $-5.14 Million |
-0.410x | -26.26% |
| 2008-06-30 | AU$22.98 Million ≈ $16.26 Million |
AU$-7.45 Million ≈ $-5.27 Million |
-0.324x | -- |
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more